Unlimited Bio, backed by Immortal Dragons, has launched a pioneering dual gene therapy trial targeting age-related muscle loss and vascular decay, marking a significant step in longevity research. The CALM-AF-AI trial, registered as NCT07443826, aims to evaluate the safety and efficacy of combining AAV9-Follistatin and VEGF plasmid gene therapies to address the multifaceted challenges of muscle deterioration as we age.

This trial is particularly noteworthy because it approaches muscle loss as a systems-level problem rather than a singular issue. By blocking myostatin to facilitate muscle growth and promoting the development of new blood vessels, the therapy seeks to enhance both muscle mass and the supportive vascular network. This dual-action strategy aligns with emerging trends in longevity therapeutics that emphasize combination therapies to tackle interconnected aging-related declines.

For professionals in the field, the CALM-AF-AI trial serves as a reminder of the importance of addressing the broader implications of aging. If successful, it could pave the way for innovative treatment paradigms that prioritize functional outcomes over traditional biomarkers, ultimately enhancing healthspan and quality of life for older adults.

Source: longevity.technology